

# Albania

Population 2015

2.9 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.01 (<0.01–0.015)	0.35 (0.22–0.51)
Mortality (HIV+TB only)	<0.01 (<0.01–<0.01)	0.05 (0–0.17)
Incidence (includes HIV+TB)	0.55 (0.46–0.63)	19 (16–22)
Incidence (HIV+TB only)	<0.01 (<0.01–0.01)	0.27 (0.21–0.34)
Incidence (MDR/RR-TB)**	0.015 (<0.01–0.027)	0.52 (0.1–0.93)

Estimated TB incidence by age and sex (thousands)*, 2015			
	0-14 years	> 14 years	Total
Females	0.018 (<0.01–0.03)	0.15 (0.091–0.22)	0.17 (0.097–0.25)
Males	0.032 (0.021–0.043)	0.34 (0.27–0.42)	0.37 (0.29–0.46)
Total	0.05 (0.036–0.064)	0.5 (0.45–0.54)	0.55 (0.46–0.63)

TB case notifications, 2015	
Total cases notified	415
Total new and relapse	415
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	44%
- % pulmonary	72%
- % bacteriologically confirmed among pulmonary	71%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2015	76% (65–89)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.02 (0.01–0.03)

TB/HIV care in new and relapse TB patients, 2015		Number	(%)
Patients with known HIV-status who are HIV-positive		6	3%
- on antiretroviral therapy		6	100%

Drug-resistant TB care, 2015			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			8 (1–15)
Estimated % of TB cases with MDR/RR-TB	2.3% (0.64–5.8)	6.7% (0.17–32)	
% notified tested for rifampicin resistance	2%	29%	13
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 4, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 3, XDR-TB: 0	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2014	88%	406
Previously treated cases, excluding relapse, registered in 2014		0
HIV-positive TB cases, all types, registered in 2014	100%	2
MDR/RR-TB cases started on second-line treatment in 2013		
XDR-TB cases started on second-line treatment in 2013		

TB preventive treatment, 2015	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	8% (5.9–12)

TB financing, 2016	
National TB budget (US\$ millions)	

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


## Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015




Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



— Unfunded  
— Funded internationally  
— Funded domestically